Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 3

Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer

Vanderbilt University Medical Center · NCT05999630

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 3
Target enrollment
100
US sites recruiting
1
Study start
August 21, 2023
Record last updated
October 28, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.

Being studied: Artificial Tears Methylcellulose

Conditions: Nasolacrimal Duct Obstruction; Thyroid Cancer

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Radio-iodine therapy for thyroid cancer
  • Radioiodine therapy ≥150 mCi
  • Age 18 or older

Exclusion Criteria

  • Use of eye drops, other than artificial tears
  • History of periocular trauma with tear duct involvement/lacrimal gland trauma
  • History of lacrimal drainage disease: canaliculitis, dacryocystitis
  • Prior radiotherapy
  • Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
  • Medical conditions that predispose to NLD stenosis (i.e. sarcoidosis, granulomatosis with polyangiitis, chronic lymphocytic leukemia)
  • Nasolacrimal duct obstruction at baseline

Recruiting US locations

  • Vanderbilt University Medical Center

    Nashville, TN 37232

    Site contact: Rachel Sobel, MD · 4152796578 · rachel.k.sobel@vumc.org

Study contacts (from the official record)

  • Marybeth Carter · 615-936-1639 · marybeth.l.carter@vumc.org
All healthy volunteers studies in Tennessee →
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in… (NCT05999630) | Bored Studies